Search

Your search keyword '"Böhmig, Georg A."' showing total 810 results
Start Over Author "Böhmig, Georg A."
810 results on '"Böhmig, Georg A."'

1. Functional Natural Killer-cell Genetics and Microvascular Inflammation After Kidney Transplantation: An Observational Cohort Study

Author

Diebold, Matthias, Vietzen, Hannes, Schatzl, Martina, Mayer, Katharina A., Haindl, Susanne, Heinzel, Andreas, Hittmeyer, Philip, Herz, Carsten T., Hopfer, Helmut, Menter, Thomas, Kühner, Laura M., Berger, Sarah M., Puchhammer-Stöckl, Elisabeth, Doberer, Konstantin, Steiger, Jürg, Schaub, Stefan, and Böhmig, Georg A.

Published
2024
Full Text
View/download PDF

2. Cilgavimab and tixagevimab as pre-exposure prophylaxis in vaccine non-responder kidney transplant recipients during a period of prevalent SARS-CoV-2 BA.2 and BA.4/5 variants—a prospective cohort study (RESCUE-TX)

Author

Reindl-Schwaighofer, Roman, Heinzel, Andreas, Raab, Lukas, Strassl, Robert, Herz, Carsten T., Regele, Florina, Doberer, Konstantin, Helk, Oliver, Spechtl, Paul, Aschauer, Constantin, Hu, Karin, Jagoditsch, Rahel, Reiskopf, Bianca, Böhmig, Georg A., Benka, Bernhard, Mahr, Benedikt, Stiasny, Karin, Weseslindtner, Lukas, Kammer, Michael, Wekerle, Thomas, and Oberbauer, Rainer

Published
2024
Full Text
View/download PDF

3. Banff 2022 Kidney Commentary: Reflections and Future Directions

Author

Rabant, Marion, Adam, Benjamin A., Aubert, Olivier, Böhmig, Georg A., Clahsen Van-Groningen, Marian, Cornell, Lynn D., de Vries, Aiko P.J., Huang, Edmund, Kozakowski, Nicolas, Perkowska-Ptasinska, Agnieszka, Riella, Leonardo V., Rosales, Ivy A., Schinstock, Carrie, Simmonds, Naomi, Thaunat, Olivier, and Willicombe, Michelle

Published
2024
Full Text
View/download PDF

4. Polyomavirus Nephropathy in ABO Blood Group-Incompatible Kidney Transplantation: Torque Teno Virus and Immunosuppressive Burden as an Approximation to the Problem

Author

Eder, Michael, Schrag, Tarek A., Havel, Ella F., Kainz, Alexander, Omic, Haris, Doberer, Konstantin, Kozakowski, Nicolas, Körmöczi, Günther F., Schönbacher, Marlies, Fischer, Gottfried, Strassl, Robert, Breuer, Monika, Weseslindtner, Lukas, Haupenthal, Frederik, Böhmig, Georg A., Puchhammer-Stöckl, Elisabeth, Bond, Gregor, Görzer, Irene, and Eskandary, Farsad

Published
2024
Full Text
View/download PDF

7. The Banff 2022 Kidney Meeting Report: Reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics

Author

Naesens, Maarten, Roufosse, Candice, Haas, Mark, Lefaucheur, Carmen, Mannon, Roslyn B., Adam, Benjamin A., Aubert, Olivier, Böhmig, Georg A., Callemeyn, Jasper, Clahsen-van Groningen, Marian, Cornell, Lynn D., Demetris, Anthony J., Drachenberg, Cinthia B., Einecke, Gunilla, Fogo, Agnes B., Gibson, Ian W., Halloran, Philip, Hidalgo, Luis G., Horsfield, Catherine, Huang, Edmund, Kikić, Željko, Kozakowski, Nicolas, Nankivell, Brian, Rabant, Marion, Randhawa, Parmjeet, Riella, Leonardo V., Sapir-Pichhadze, Ruth, Schinstock, Carrie, Solez, Kim, Tambur, Anat R., Thaunat, Olivier, Wiebe, Chris, Zielinski, Dina, Colvin, Robert, Loupy, Alexandre, and Mengel, Michael

Published
2024
Full Text
View/download PDF

8. Subthreshold rejection activity in many kidney transplants currently classified as having no rejection

Author

Halloran, Philip F., Madill-Thomsen, Katelynn S., Böhmig, Georg, Bromberg, Jonathan, Budde, Klemens, Barner, Meagan, Mackova, Martina, Chang, Jessica, Einecke, Gunilla, Eskandary, Farsad, Gupta, Gaurav, Myślak, Marek, Viklicky, Ondrej, Akalin, Enver, Alhamad, Tarek, Anand, Sanjiv, Arnol, Miha, Baliga, Rajendra, Banasik, Mirosław, Bingaman, Adam, Blosser, Christopher D., Brennan, Daniel, Chamienia, Andrzej, Chow, Kevin, Ciszek, Michał, de Freitas, Declan, Dęborska-Materkowska, Dominika, Debska-Ślizień, Alicja, Djamali, Arjang, Domański, Leszek, Durlik, Magdalena, Fatica, Richard, Francis, Iman, Fryc, Justyna, Gill, John, Gill, Jagbir, Glyda, Maciej, Gourishankar, Sita, Grenda, Ryszard, Gryczman, Marta, Hruba, Petra, Hughes, Peter, Jittirat, Arskarapurk, Jurekovic, Zeljka, Kamal, Layla, Kamel, Mahmoud, Kant, Sam, Kasiske, Bertram, Kojc, Nika, Konopa, Joanna, Lan, James, Mannon, Roslyn, Matas, Arthur, Mazurkiewicz, Joanna, Miglinas, Marius, Müller, Thomas, Narins, Seth, Naumnik, Beata, Patel, Anita, Perkowska-Ptasińska, Agnieszka, Picton, Michael, Piecha, Grzegorz, Poggio, Emilio, Bloudíčkova, Silvie Rajnochová, Samaniego-Picota, Milagros, Schachtner, Thomas, Shin, Sung, Shojai, Soroush, Sikosana, Majid L.N., Slatinská, Janka, Smykal-Jankowiak, Katarzyna, Solanki, Ashish, Veceric Haler, Željka, Vucur, Ksenija, Weir, Matthew R., Wiecek, Andrzej, Włodarczyk, Zbigniew, Yang, Harold, and Zaky, Ziad

Published
2024
Full Text
View/download PDF

9. A multicentre, patient- and assessor-blinded, non-inferiority, randomised and controlled phase II trial to compare standard and torque teno virus-guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT

Author

Haupenthal, Frederik, Rahn, Jette, Maggi, Fabrizio, Gelas, Fanny, Bourgeois, Philippe, Hugo, Christian, Jilma, Bernd, Böhmig, Georg A., Herkner, Harald, Wolzt, Michael, Doberer, Konstantin, Vossen, Matthias, Focosi, Daniele, Neuwirt, Hannes, Banas, Miriam, Banas, Bernhard, Budde, Klemens, Viklicky, Ondrej, Malvezzi, Paolo, Rostaing, Lionel, Rotmans, Joris I., Bakker, Stephan J. L., Eller, Kathrin, Cejka, Daniel, Pérez, Alberto Molina, Rodriguez-Arias, David, König, Franz, and Bond, Gregor

Published
2023
Full Text
View/download PDF

10. Using Regression Equations to Enhance Interpretation of Histology Lesions of Kidney Transplant Rejection

Author

Sikosana, Majid L.N., Reeve, Jeff, Madill-Thomsen, Katelynn S., Halloran, Philip F., Mannon, Roslyn, Serón, Daniel, Sellares, Joanna, Akalin, Enver, de Freitas, Declan, Picton, Michael, Bromberg, Jonathan, Weir, Matt, Budde, Klemens, Heinbokel, Timm, Einecke, Gunilla, Yang, Harold, Narins, Seth, Samaniego-Picota, Milagros, Myslak, Marek, Perkowska-Ptasinska, Agnieszka, Bingaman, Adam, Brennan, Daniel, Malone, Andrew, Kasiske, Bertram, Matas, Arthur, Djamali, Arjang, Böhmig, Georg, Eskandary, Farsad, and Gupta, Gaurav

Published
2024
Full Text
View/download PDF

14. Using Regression Equations to Enhance Interpretation of Histology Lesions of Kidney Transplant Rejection

Author

Sikosana, Majid L.N., Reeve, Jeff, Madill-Thomsen, Katelynn S., Halloran, Philip F., Mannon, Roslyn, Serón, Daniel, Sellares, Joanna, Akalin, Enver, de Freitas, Declan, Picton, Michael, Bromberg, Jonathan, Weir, Matt, Budde, Klemens, Heinbokel, Timm, Einecke, Gunilla, Yang, Harold, Narins, Seth, Samaniego-Picota, Milagros, Myslak, Marek, Perkowska-Ptasinska, Agnieszka, Bingaman, Adam, Brennan, Daniel, Malone, Andrew, Kasiske, Bertram, Matas, Arthur, Djamali, Arjang, Böhmig, Georg, Eskandary, Farsad, and Gupta, Gaurav

Published
2023
Full Text
View/download PDF

16. Allograft and patient survival after sequential HSCT and kidney transplantation from the same donor—A multicenter analysis

Author

Eder, Michael, Schwarz, Christoph, Kammer, Michael, Jacobsen, Niels, Stavroula, Masouridi Levrat, Cowan, Morton J, Chongkrairatanakul, Tepsiri, Gaston, Robert, Ravanan, Rommel, Ishida, Hideki, Bachmann, Anette, Alvarez, Sergio, Koch, Martina, Garrouste, Cyril, Duffner, Ulrich A, Cullis, Brett, Schaap, Nicolaas, Medinger, Michael, Sørensen, Søren Schwartz, Dauber, Eva‐Maria, Böhmig, Georg, Regele, Heinz, Berlakovich, Gabriela A, Wekerle, Thomas, and Oberbauer, Rainer

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Stem Cell Research, Clinical Research, Kidney Disease, Transplantation, Organ Transplantation, Regenerative Medicine, 6.4 Surgery, Evaluation of treatments and therapeutic interventions, Renal and urogenital, Adolescent, Adult, Allografts, Case-Control Studies, Combined Modality Therapy, Female, Follow-Up Studies, Graft Survival, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppressive Agents, Kidney Failure, Chronic, Kidney Transplantation, Living Donors, Male, Middle Aged, Prognosis, Risk Factors, Survival Rate, Transplantation, Homologous, Young Adult, bone marrow, hematopoietic stem cell transplantation, clinical research, practice, kidney (allograft) function, dysfunction, kidney transplantation, nephrology, tolerance: clinical, bone marrow/hematopoietic stem cell transplantation, clinical research/practice, kidney (allograft) function/dysfunction, kidney transplantation/nephrology, Medical and Health Sciences, Surgery, Clinical sciences, Immunology
Abstract

Tolerance induction through simultaneous hematopoietic stem cell and renal transplantation has shown promising results, but it is hampered by the toxicity of preconditioning therapies and graft-versus-host disease (GVHD). Moreover, renal function has never been compared to conventionally transplanted patients, thus, whether donor-specific tolerance results in improved outcomes remains unanswered. We collected follow-up data of published cases of renal transplantations after hematopoietic stem cell transplantation from the same donor and compared patient and transplant kidney survival as well as function with caliper-matched living-donor renal transplantations from the Austrian dialysis and transplant registry. Overall, 22 tolerant and 20 control patients were included (median observation period 10 years [range 11 months to 26 years]). In the tolerant group, no renal allograft loss was reported, whereas 3 were lost in the control group. Median creatinine levels were 85 μmol/l (interquartile range [IQR] 72-99) in the tolerant cohort and 118 μmol/l (IQR 99-143) in the control group. Mixed linear-model showed around 29% lower average creatinine levels throughout follow-up in the tolerant group (P

Published
2019

18. Opinions on the Future of Clinical Pig Kidney Xenotransplantation.

Author

Böhmig, Georg A., Diebold, Matthias, and Budde, Klemens

Subjects
*XENOGRAFTS, *XENOTRANSPLANTATION, *KIDNEY transplantation, *CLINICAL medicine, *GENOME editing
Abstract

Based on promising results obtained in primate models, pioneers in the US have now started to explore the new frontier of genetically-edited pig-to-human transplantation. The recent transition of xenotransplantation into clinical medicine has included transplants in brain-dead subjects and the compassionate use of xenotransplants in living recipients without options for allotransplantation. While the barrier of hyperacute rejection seems to be successfully overcome by gene editing of donor pigs, the occurrence of accelerated rejection could pose significant limitations to the success of the procedure. Ultimately, the establishment of efficient and safe strategies to overcome immunologic barriers will, among other critical factors, such as potential xenozoonotic disease transmission or physiological differences, determine whether and for which indications xenotransplantation will be viable. Considering preliminary outcomes of compassionate use xenotransplantions, which may raise questions about how faithfully data from non-human primate models translate into human outcomes, further research in decedents may be necessary before proceeding with additional clinical transplants. Looking ahead, designing systematic trials in xenotransplantation, including the definition of acceptable eligibility criteria for such high-risk transplants, will be an immense challenge, especially in kidney transplantation, where dialysis provides an effective alternative to transplantation in most cases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Torque Teno Virus Control by the Classical Pathway of Complement Activation—A Retrospective Analysis From a First‐in‐Human Trial Utilizing Sutimlimab.

Author

Kapps, Sebastian, Mühlbacher, Jakob, Kulifaj, Dorian, Courjal, Sophie, Eskandary, Farsad, Schiemann, Martin, Jilma, Bernd, Böhmig, Georg A., Bond, Gregor, and Wahrmann, Markus

Subjects
TORQUE teno virus, KIDNEY transplantation, BODY weight, IMMUNE system, TREND analysis
Abstract

Torque Teno virus (TTV) load is linked with the functionality of its host's immune system and has been proposed as a potential monitoring tool for immune‐modulating therapy. However, the immunological mechanisms of TTV control are incompletely understood. To assess the effect of the classical complement pathway on TTV, 64 healthy volunteers and 10 kidney transplant recipients treated with the anti‐C1s antibody sutimlimab were analyzed for serum TTV copy numbers (c/mL) by qPCR. Overall, a correlation was observed between the decrease in complement activity caused by sutimlimab and the TTV load increase (ρ = −0.367, p < 0.001). Subgroup analysis indicated a trend toward TTV load increase in healthy volunteers following the highest sutimlimab dose compared to baseline (100 mg/kg body weight; median 3.5 log10 c/mL, interquartile range [IQR] 2.8–4.4 vs. 2.9 log10 c/mL, 0.8–3.5; p = 0.063). Administering multiple lower doses (30 mg/kg) also showed a trend toward TTV load increase in healthy volunteers (1.8 log10 c/mL, 0–2.3 vs. 1.9, 1.3–2.8; p = 0.054) and a significant increase in transplant recipients (3.5 log10 c/mL, 3.0–6.1 vs. 4.1, 3.5–6.4; p = 0.004). This report suggests a role for the classical complement pathway in controlling TTV load. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial

Author

Mayer, Katharina A., Budde, Klemens, Halloran, Philip F., Doberer, Konstantin, Rostaing, Lionel, Eskandary, Farsad, Christamentl, Anna, Wahrmann, Markus, Regele, Heinz, Schranz, Sabine, Ely, Sarah, Firbas, Christa, Schörgenhofer, Christian, Kainz, Alexander, Loupy, Alexandre, Härtle, Stefan, Boxhammer, Rainer, Jilma, Bernd, and Böhmig, Georg A.

Published
2022
Full Text
View/download PDF

23. A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection

Author

Mayer, Katharina A., primary, Schrezenmeier, Eva, additional, Diebold, Matthias, additional, Halloran, Philip F., additional, Schatzl, Martina, additional, Schranz, Sabine, additional, Haindl, Susanne, additional, Kasbohm, Silke, additional, Kainz, Alexander, additional, Eskandary, Farsad, additional, Doberer, Konstantin, additional, Patel, Uptal D., additional, Dudani, Jaideep S., additional, Regele, Heinz, additional, Kozakowski, Nicolas, additional, Kläger, Johannes, additional, Boxhammer, Rainer, additional, Amann, Kerstin, additional, Puchhammer-Stöckl, Elisabeth, additional, Vietzen, Hannes, additional, Beck, Julia, additional, Schütz, Ekkehard, additional, Akifova, Aylin, additional, Firbas, Christa, additional, Gilbert, Houston N., additional, Osmanodja, Bilgin, additional, Halleck, Fabian, additional, Jilma, Bernd, additional, Budde, Klemens, additional, and Böhmig, Georg A., additional

Published
2024
Full Text
View/download PDF

24. Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study

Author

Raynaud, Marc, Aubert, Olivier, Divard, Gillian, Reese, Peter P, Kamar, Nassim, Yoo, Daniel, Chin, Chen-Shan, Bailly, Élodie, Buchler, Matthias, Ladrière, Marc, Le Quintrec, Moglie, Delahousse, Michel, Juric, Ivana, Basic-Jukic, Nikolina, Crespo, Marta, Silva, Helio Tedesco, Jr, Linhares, Kamilla, Ribeiro de Castro, Maria Cristina, Soler Pujol, Gervasio, Empana, Jean-Philippe, Ulloa, Camilo, Akalin, Enver, Böhmig, Georg, Huang, Edmund, Stegall, Mark D, Bentall, Andrew J, Montgomery, Robert A, Jordan, Stanley C, Oberbauer, Rainer, Segev, Dorry L, Friedewald, John J, Jouven, Xavier, Legendre, Christophe, Lefaucheur, Carmen, and Loupy, Alexandre

Published
2021
Full Text
View/download PDF

27. Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation

Author

Raynaud, Marc, Aubert, Olivier, Reese, Peter P., Bouatou, Yassine, Naesens, Maarten, Kamar, Nassim, Bailly, Élodie, Giral, Magali, Ladrière, Marc, Le Quintrec, Moglie, Delahousse, Michel, Juric, Ivana, Basic-Jukic, Nikolina, Gupta, Gaurav, Akalin, Enver, Yoo, Daniel, Chin, Chen-Shan, Proust-Lima, Cécile, Böhmig, Georg, Oberbauer, Rainer, Stegall, Mark D., Bentall, Andrew J., Jordan, Stanley C., Huang, Edmund, Glotz, Denis, Legendre, Christophe, Montgomery, Robert A., Segev, Dorry L., Empana, Jean-Philippe, Grams, Morgan E., Coresh, Josef, Jouven, Xavier, Lefaucheur, Carmen, and Loupy, Alexandre

Published
2021
Full Text
View/download PDF

30. Kidney Paired Donation—European Transnational Experience in Adults and Opportunities for Pediatric Kidney Transplantation.

Author

Böhmig, Georg A., Müller‐Sacherer, Thomas, and Viklicky, Ondrej

Subjects
*BLOOD group incompatibility, *ABO blood group system, *KIDNEY transplantation, *CHILD patients, *ORGAN donation
Abstract

Background: Live donor kidney transplantation is considered the optimal choice for renal replacement therapy, providing established benefits, such as superior patient survival and improved quality of life. However, immunological challenges, including ABO blood group incompatibility and, particularly, donor‐specific HLA antibodies, may impact long‐term outcomes considerably or even prevent safe direct transplantation with the intended donor. Methods: In this review, the authors discuss kidney paired donation (KPD) as a viable strategy to overcome immunological barriers to living donation through organ exchanges. We thereby lay special focus on the Czech‐Austrian transnational KPD program. Results: While the benefits of KPD programs are well established for adult recipients, recent data suggest that this may hold true also for pediatric patients. Complex algorithms, considering factors like the intricate patterns of HLA sensitization, play a pivotal role in predicting suitable matches, but for pediatric patients also non‐immunological factors including age and weight match may play a role. As pool size proves crucial for program efficacy, several countries in Europe have now initiated transnational collaborations to maximize match rates. Among those, the Czech‐Austrian transnational joint program, established in 2015 and now expanded to a cooperation with the Israel transplant program to further increase transplant rates, represents a successful example. Conclusion: KPD programs, with their innovative approaches and international partnerships, hold promise for enhancing outcomes and addressing the increasing demand for kidney transplantation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Natural Killer Cell Presence in Antibody-Mediated Rejection.

Author

Diebold, Matthias, Farkash, Evan A., Barnes, Jenna, Regele, Heinz, Kozakowski, Nicolas, Schatzl, Martina, Mayer, Katharina A., Haindl, Susanne, Vietzen, Hannes, Hidalgo, Luis G., Halloran, Philip F., Eskandary, Farsad, and Böhmig, Georg A.

Subjects
KILLER cells, GRAFT rejection, KIDNEY transplantation, GRAFT survival, GENETIC variation
Abstract

Transcript analyses highlight an important contribution of natural killer (NK) cells to microvascular inflammation (MVI) in antibody-mediated rejection (ABMR), but only few immunohistologic studies have quantified their spatial distribution within graft tissue. This study included 86 kidney transplant recipients who underwent allograft biopsies for a positive donor-specific antibody (DSA) result. NK cells were visualized and quantified within glomeruli and peritubular capillaries (PTC), using immunohistochemistry for CD34 alongside CD16/T-bet double-staining. Staining results were analyzed in relation to histomorphology, microarray analysis utilizing the Molecular Microscope Diagnostic System, functional NK cell genetics, and clinical outcomes. The number of NK cells in glomeruli per mm2 glomerular area (NKglom) and PTC per mm2 cortical area (NKPTC) was substantially higher in biopsies with ABMR compared to those without rejection, and correlated with MVI scores (NKglom Spearman's correlation coefficient [SCC] = 0.55, p < 0.001, NKPTC 0.69, p < 0.001). In parallel, NK cell counts correlated with molecular classifiers reflecting ABMR activity (ABMRprob: NKglom 0.59, NKPTC 0.75) and showed a trend towards higher levels in association with high functional FCGR3A and KLRC2 gene variants. Only NKPTC showed a marginally significant association with allograft function and survival. Our immunohistochemical results support the abundance of NK cells in DSApositive ABMR. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. A Randomized Trial Comparing Imlifidase to Plasmapheresis in Kidney Transplant Recipients With Antibody‐Mediated Rejection.

Author

Halleck, Fabian, Böhmig, Georg A., Couzi, Lionel, Rostaing, Lionel, Einecke, Gunilla, Lefaucheur, Carmen, Legendre, Christophe, Montgomery, Robert, Hughes, Peter, Chandraker, Anil, Wyburn, Kate, Halloran, Phil, Maldonado, Angela Q., Sjöholm, Kristoffer, Runström, Anna, Lefèvre, Paola, Tollemar, Jan, and Jordan, Stanley

Subjects
*GRAFT rejection, *KIDNEY transplantation, *PLASMAPHERESIS, *PLASMA exchange (Therapeutics), *GRAFT survival
Abstract

Background: Antibody‐mediated rejection (ABMR) poses a barrier to long‐term graft survival and is one of the most challenging events after kidney transplantation. Removing donor specific antibodies (DSA) through therapeutic plasma exchange (PLEX) is a cornerstone of antibody depletion but has inconsistent effects. Imlifidase is a treatment currently utilized for desensitization with near‐complete inactivation of DSA both in the intra‐ and extravascular space. Methods: This was a 6‐month, randomized, open‐label, multicenter, multinational trial conducted at 14 transplant centers. Thirty patients were randomized to either imlifidase or PLEX treatment. The primary endpoint was reduction in DSA level during the 5 days following the start of treatment. Results: Despite considerable heterogeneity in the trial population, DSA reduction as defined by the primary endpoint was 97% for imlifidase compared to 42% for PLEX. Additionally, imlifidase reduced DSA to noncomplement fixing levels, whereas PLEX failed to do so. After antibody rebound in the imlifidase arm (circa days 6–12), both arms had similar reductions in DSA. Five allograft losses occurred during the 6 months following the start of ABMR treatment—four within the imlifidase arm (18 patients treated) and one in the PLEX arm (10 patients treated). In terms of clinical efficacy, the Kaplan–Meier estimated graft survival was 78% for imlifidase and 89% for PLEX, with a slightly higher eGFR in the PLEX arm at the end of the trial. The observed adverse events in the trial were as expected, and there were no apparent differences between the arms. Conclusion: Imlifidase was safe and well‐tolerated in the ABMR population. Despite meeting the primary endpoint of maximum DSA reduction compared to PLEX, the trial was unsuccessful in demonstrating a clinical benefit of imlifidase in this heterogenous ABMR population. Trial Registration: EudraCT number: 2018‐000022‐66, 2020‐004777‐49; ClinicalTrials.gov identifier: NCT03897205, NCT04711850 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Prediction system for risk of allograft loss in patients receiving kidney transplants : international derivation and validation study

Author

Loupy, Alexandre, Aubert, Olivier, Orandi, Babak J, Naesens, Maarten, Bouatou, Yassine, Raynaud, Marc, Divard, Gillian, Jackson, Annette M, Viglietti, Denis, Giral, Magali, Kamar, Nassim, Thaunat, Olivier, Morelon, Emmanuel, Delahousse, Michel, Kuypers, Dirk, Hertig, Alexandre, Rondeau, Eric, Bailly, Elodie, Eskandary, Farsad, Böhmig, Georg, Gupta, Gaurav, Glotz, Denis, Legendre, Christophe, Montgomery, Robert A, Stegall, Mark D, Empana, Jean-Philippe, Jouven, Xavier, Segev, Dorry L, and Lefaucheur, Carmen

Published
2019

41. Contribution of non-HLA incompatibility between donor and recipient to kidney allograft survival: genome-wide analysis in a prospective cohort

Author

Reindl-Schwaighofer, Roman, Heinzel, Andreas, Kainz, Alexander, van Setten, Jessica, Jelencsics, Kira, Hu, Karin, Loza, Bao-Li, Kammer, Michael, Heinze, Georg, Hruba, Petra, Koňaříková, Alena, Viklicky, Ondrej, Boehmig, Georg A, Eskandary, Farsad, Fischer, Gottfried, Claas, Frans, Tan, John C, Albert, Tom J, Patel, Jigar, Keating, Brendan, and Oberbauer, Rainer

Published
2019
Full Text
View/download PDF

42. Allograft rejection is associated with development of functional IgE specific for donor MHC antigens

Author

Farkas, Andreas M., Baranyi, Ulrike, Böhmig, Georg A., Unger, Lukas, Hopf, Stefan, Wahrmann, Markus, Regele, Heinz, Mahr, Benedikt, Schwarz, Christoph, Hock, Karin, Pilat, Nina, Kristo, Ivan, Mraz, Jasmin, Lupinek, Christian, Thalhamer, Josef, Bond, Gregor, Kuessel, Lorenz, Wlodek, Elizabeth, Martin, Jack, Clatworthy, Menna, Pettigrew, Gavin, Valenta, Rudolf, and Wekerle, Thomas

Published
2019
Full Text
View/download PDF

43. Quo vadis?

Author

Feucht, Helmut E. and Böhmig, Georg A.

Subjects
*IMMUNOLOGY, *ARTIFICIAL intelligence, *PATHOLOGY, *HUMORAL immunity, *CELLULAR immunity
Abstract

The article focuses on advancements in transplantation immunology, acknowledging historical shifts in understanding immune responses to transplants, particularly between cellular and humoral immunity paradigms. It explores the shift from focusing solely on T-cell-mediated rejection to a comprehensive view involving B-cells, NK cells, and the interaction of innate and acquired immunity, while also highlighting the use of artificial intelligence in pathology.

Published
2024
Full Text
View/download PDF

45. Natural killer cell functional genetics and donor-specific antibody-triggered microvascular inflammation

Author

Diebold, Matthias, primary, Vietzen, Hannes, additional, Heinzel, Andreas, additional, Haindl, Susanne, additional, Herz, Carsten T., additional, Mayer, Katharina, additional, Doberer, Konstantin, additional, Kainz, Alexander, additional, Faé, Ingrid, additional, Wenda, Sabine, additional, Kühner, Laura M., additional, Berger, Sarah M., additional, Puchhammer-Stöckl, Elisabeth, additional, Kozakowski, Nicolas, additional, Schaub, Stefan, additional, Halloran, Philip F., additional, and Böhmig, Georg A., additional

Published
2023
Full Text
View/download PDF

46. The Banff 2022 Kidney Meeting Report: Re-Appraisal of Microvascular Inflammation and the Role of Biopsy-Based Transcript Diagnostics

Author

Naesens, Maarten, primary, Roufosse, Candice, additional, Haas, Mark, additional, Lefaucheur, Carmen, additional, Mannon, Roslyn B., additional, Adam, Benjamin A., additional, Aubert, Olivier, additional, Böhmig, Georg A., additional, Callemeyn, Jasper, additional, Groningen, Marian Clahsen-van, additional, Cornell, Lynn D., additional, Demetris, Anthony J., additional, Drachenberg, Cinthia B., additional, Einecke, Gunilla, additional, Fogo, Agnes B., additional, Gibson, Ian W., additional, Halloran, Philip, additional, Hidalgo, Luis G., additional, Horsfield, Catherine, additional, Huang, Edmund, additional, Kikić, Željko, additional, Kozakowski, Nicolas, additional, Nankivell, Brian, additional, Rabant, Marion, additional, Randhawa, Parmjeet, additional, Riella, Leonardo V., additional, Sapir-Pichhadze, Ruth, additional, Schinstock, Carrie, additional, Solez, Kim, additional, Tambur, Anat R., additional, Thaunat, Olivier, additional, Wiebe, Chris, additional, Zielinski, Dina, additional, Colvin, Robert, additional, Loupy, Alexandre, additional, and Mengel, Michael, additional

Published
2023
Full Text
View/download PDF

47. Torque Teno Virus Load Is Associated With Sub-Clinical Alloreactivity in Kidney Transplant Recipients: A Prospective Observational Trial

Author

Doberer, Konstantin, Haupenthal, Frederik, Nackenhorst, Maja, Bauernfeind, Florian, Dermuth, Florentina, Eigenschink, Michael, Schiemann, Martin, Kläger, Johannes, Görzer, Irene, Eskandary, Farsad, Reindl-Schwaighofer, Roman, Kikić, Željko, Böhmig, Georg, Strassl, Robert, Regele, Heinz, Puchhammer-Stöckl, Elisabeth, and Bond, Gregor

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results